Effectiveness of therapies for mental disorders: real clinical practice versus scientific evidence

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article provides information on particular issues of treatment of mental disorders. An analysis was made of the issues of therapeutic resistance and compliance among mental patients, which play an important role in possible discrepancies between the results of randomized placebo-controlled trials and the use of psychotropic drugs in routine clinical practice. The main aspects of clinical pharmacology are presented in an accessible form, which determine the complexity and at the same time professionalism in the practice of a psychiatrist. Grouped and deciphered are the factors that have a direct impact on the therapeutic response of the drug, including the primary pharmacological properties of the drug, nosological, general biological, social, subjective-psychological factors.

Full Text

Restricted Access

About the authors

Timur R. Gazizullin

Kazan State Medical University

Email: kary85@mail.ru
ORCID iD: 0000-0002-3100-6291
SPIN-code: 8872-3118

Cand.Sci. (Med.), Assistant

Russian Federation, 420012, Kazan, Butlerova str., 49

Alexander G. Zhidyaevskij

Kazan State Medical University

Author for correspondence.
Email: zhidyaevskij@mail.ru
ORCID iD: 0000-0002-4245-5201
SPIN-code: 5865-6771

assistant of the Department of Psychiatry and Medical psycholog

Russian Federation, 420012, Kazan, Butlerova str., 49

References

  1. Avruckij GYа, Neduva AA. Lechenie psihicheskih bolnyh. Rukovodstvo dlya vrachej. 2-e izd. Moscow: Medicina; 1988. 528 p. (In Russ.)
  2. Sperry L. Psychopharmacology and Psychotherapy: Strategies for Maximizing Treatment Outcomes. NewYork: Brunner/Mazel; 1995. 50 p.
  3. Vedisova AS. Novye problemy psihofarmakoterapii. Moscow: FGU GNC SSP im. V.P. Serbskogo; 2005. 170 p. (In Russ.)
  4. Mosolov SN. Rezistentnost k psihofarmakoterapii i metody eyo preodoleniya. Psihiatriya i psihofarmakoterapiya. 2002;4(4):132–136. (In Russ.) doi: 10.24411/1560-957X-2015-1%25x.
  5. Mosolov SN. Sovremennyj etap razvitiya psihofarmakoterapii. Russkij medicinskij zhurnal. 2002;10(12/13):45–49. (In Russ.)
  6. Kane JM. Factors which can make patient difficult to treat. Brit J Psych. 1996;169(31):10–14.
  7. Vinnikova IN, Borisov DV. Prediktory terapevticheskoj rezistentnosti u bolnyh paranoidnoj shizofreniej. Rossijskij psihiatricheskij zhurnal. 2015;16(4):74–79. (In Russ.)
  8. Muzychenko AP, Dmitrenkov SI, Zakhatsky AN et al. Terapevticheskaya rezistentnost pri pristupoobrazno protekayushej shizofrenii i metody ee korrekcii. Lipetsk: Infol; 2002. 120 p. (In Russ.)
  9. Gurovich IY, Shmukler AB, Dorodnova AS et al. Resociali-ziruyushij effekt antipsihotikov v kompleksnoj terapii bolnyh s vpervye voznikshimi psihoticheskimi sostoyaniyami. Socialnaya i klinicheskaya psihiatriya. 2011;21(1):43–48. (In Russ.)
  10. Bergfeld IO, Mantione M, Figee M et al. Treatment-resistant depression and suicidality. J. Affect Disord. 2018;1(235):362–367. doi: 10.1016/j.jad.2018.04.016.
  11. Kozlovskij VL, Popov MYu. Biologicheskie predposylki formirovaniya lekarstvennoj rezistentnosti v psihiatrii i farmakodinamicheskie podhody k ee preodoleniyu. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2020;120(10):137–142. (In Russ.)
  12. Morozova MA. Rezistentnost k antipsihotikam i vozmozhnosti olanzapina v refrakternyh k terapii sluchayah shizofrenii. Psihiatriya i psihofarmakoterapiya. 2002;3:113–117. (In Russ.)
  13. Maksimov VI. Patomorfoz psihicheskih zabolevanij. Sovremennaya terapiya v psihiatrii i nevrologii. 2016;4:14–18. (In Russ.)
  14. Ivanov MV, Sosin DN, Shamanina MV et al. Geneticheskie markery terapevticheskoj rezistentnosti pri shizofrenii. Sovremennaya terapiya psihicheskih rasstrojstv. 2018;3:2–11. (In Russ.) doi: 10.21265/PSYPH.2018.46.16766.
  15. Julia B, Arthur C, Adam MC et al. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial. Lancet Psychiatry. 2020;7(4):337–343. doi: 10.1016/S2215-0366(20)30060-2.
  16. Bykov YuV. Rezistentnye k terapii depressii. Stavropol: [b. i.]; 2009. 74 p. (In Russ.)
  17. Malin DI. Sovremennye podhody k probleme intolerantnosti k psihofarmakoterapii u bolnyh endogennymi psihozami. Psihiatriya i psihofarmakoterapiya. 2003;5(1):38–40. (In Russ.)
  18. Murray RM, Quattrone D, Natesan S et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry. 2016;209(5):361–365. doi: 10.1192/bjp.bp.116.182683. PMID: 27802977. S2CID 3402263.
  19. Fawcett J. Compliance: definitions and key issues. J Clin Psychiatry. 1995;56:4–10.
  20. Byerly M, Fisher R, Rush AJ et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adhe-rence in outpatients with schizophrenia. Psychiatry Research. 2005;133(2–3):33–129.
  21. Banshikov FR. Komplaens v psihiatrii: realnost i perspektivy. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Behtereva. 2006;4:20–25. (In Russ.)
  22. Vagina MA, Volkova LI. Analiz prichin nizkoj priverzhennosti protivoepilepticheskoj terapii u bolnyh simptomaticheskoj epilepsiej. Nevrologiya, nejropsihiatriya, psihosomatika. 2014;3:17–20. (In Russ.)
  23. Alieva LM, Solohina TA. Socialno-psihologicheskie faktory komplaentnosti bolnyh shizofreniej. Psihiatriya. 2020;18(2):71–81. (In Russ.) doi: 10.30629/2618-6667-2020-18-2-71-81.
  24. Littrell K, Jones-Vaughn JE, MacFariane J. Soblyudenie rezhima lecheniya v psihiatrii: chto dolzhen znat kazhdyj vrach, lechashij bolnyh shizofreniej (referat). Psihiatriya i psihofarmakoterapiya. 2005;7:25–31. (In Russ.)
  25. McIntosh AM, Conlon L, Lawrie SM et al. Compliance therapy for schizophrenia. The Cochrane Database of Systematic Reviews. 2006;3(3):44–53. doi: 10.1002/14651858. CD003442.pub2. PMC: 7017223. PMID: 16856009.
  26. Olfson M, Marcus SC, Wilk J et al. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatric Services. 2006;57(2):205–211. doi: 10.1176/appi.ps.57.2.205. PMID: 16452697.
  27. Lutova NB. Komplaens v psihiatrii i podhody k ego uluchsheniyu. Rossijskij psihiatricheskij zhurnal. 2012;2:20–24. (In Russ.)
  28. Morozov PV. Priverzhennost terapii: vzglyad iz Evropy i poziciya otechestvennyh psihiatrov. Psihiatriya i psihofarmakoterapiya. 2010;5:49–50. (In Russ.)
  29. Dolder CR, Lacro JP, Leckband S et al. Interventions to improve antipsychotic medication adherence: review of recent literature. Journal of Clinical Psychopharmacology. 2003;23(4):389–399. DOI: 1097/01.jcp.0000085413.08426.41. PMID: 12920416.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Gazizullin T.R., Zhidyaevskij A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies